Imaging Biomarker for Early-Stage Alzheimer Disease: Utility of Hippocampal Histogram Analysis of Diffusion Metrics

References

1. 1.↵
   1. Petersen RC

   . Clinical practice. Mild cognitive impairment. N Engl J Med 2011;364:2227–34 doi:10.1056/NEJMcp0910237 pmid:21651394

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Henneman WJP,
   2. Vrenken H,
   3. Barnes J, et al

   . Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. Neurology 2009;73:935–40 doi:10.1212/WNL.0b013e3181b879ac pmid:19770469

   Abstract/FREE Full Text
3. 3.↵
   1. Blennow K,
   2. Hampel H

   . CSF markers for incipient Alzheimer's disease. Lancet Neurol 2003;2:605–13 doi:10.1016/s1474-4422(03)00530-1 pmid:14505582

   CrossRefPubMedWeb of Science
4. 4.↵
   1. Herukka SK,
   2. Hallikainen M,
   3. Soininen H, et al

   . CSF Aβ42 and tau or phosphorylated tau and prediction of progressive mild cognitive impairment. Neurology 2005;64:1294–97 doi:10.1212/01.WNL.0000156914.16988.56 pmid:15824371

   Abstract/FREE Full Text
5. 5.↵
   1. Hansson O,
   2. Zetterberg H,
   3. Buchhave P, et al

   . Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol 2006;5:228–34 doi:10.1016/S1474-4422(06)70355-6 pmid:16488378

   CrossRefPubMedWeb of Science
6. 6.↵
   1. Tapiola T,
   2. Alafuzoff I,
   3. Herukka SK, et al

   . Cerebrospinal fluid β-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain. Arch Neurol 2009;66:382–89 doi:10.1001/archneurol.2008.596 pmid:19273758

   CrossRefPubMedWeb of Science
7. 7.↵
   1. Santangelo R,
   2. Masserini F,
   3. Agosta F, et al

   . CSF p-tau/Aβ42 ratio and brain FDG-PET may reliably detect MCI “imminent” converters to AD. Eur J Nucl Med Mol Imaging 2020;47:3152–64 doi:10.1007/s00259-020-04853-4 pmid:32415550

   CrossRefPubMed
8. 8.↵
   1. Assaf Y,
   2. Pasternak O

   . Diffusion tensor imaging (DTI)-based white matter mapping in brain research: a review. J Mol Neurosci 2008;34:51–61 doi:10.1007/s12031-007-0029-0 pmid:18157658

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Horsfield MA,
   2. Jones DK

   . Applications of diffusion‐weighted and diffusion tensor MRI to white matter diseases–a review. NMR Biomed 2002;15:570–77 doi:10.1002/nbm.787 pmid:12489103

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Alexander DC,
    2. Barker GJ,
    3. Arridge SR

    . Detection and modeling of non-Gaussian apparent diffusion coefficient profiles in human brain data. Magn Reson Med 2002;48:331–40 doi:10.1002/mrm.10209 pmid:12210942

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Syková E,
    2. Nicholson C

    . Diffusion in brain extracellular space. Physiol Rev 2008;88:1277–340 doi:10.1152/physrev.00027.2007 pmid:18923183

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Zhang H,
    2. Schneider T,
    3. Wheeler-Kingshott CA, et al

    . NODDI: practical in vivo neurite orientation dispersion and density imaging of the human brain. Neuroimage 2012;61:1000–16 doi:10.1016/j.neuroimage.2012.03.072 pmid:22484410

    CrossRefPubMed
13. 13.↵
    1. Yushkevich PA,
    2. Pluta JB,
    3. Wang H, et al

    . Automated volumetry and regional thickness analysis of hippocampal subfields and medial temporal cortical structures in mild cognitive impairment. Hum Brain Mapp 2015;36:258–87 doi:10.1002/hbm.22627 pmid:25181316

    CrossRefPubMedWeb of Science
14. 14.↵
    1. Yassa MA,
    2. Stark CEL

    . Pattern separation in the hippocampus. Trends Neurosci 2011;34:515–25 doi:10.1016/j.tins.2011.06.006 pmid:21788086

    CrossRefPubMedWeb of Science
15. 15.↵
    1. O'Bryant SE,
    2. Lacritz LH,
    3. Hall J, et al

    . Validation of the new interpretive guidelines for the clinical dementia rating scale sum of boxes score in the national Alzheimer's coordinating center database. Arch Neurol 2010;67:746–49 doi:10.1001/archneurol.2010.115 pmid:20558394

    CrossRefPubMed
16. 16.↵
    1. Jenkinson M,
    2. Beckmann CF,
    3. Behrens TE, et al

    . FSL. Neuroimage 2012;62:782–90 doi:10.1016/j.neuroimage.2011.09.015 pmid:21979382

    CrossRefPubMedWeb of Science
17. 17.↵
    1. Andersson JL,
    2. Skare S,
    3. Ashburner J

    . How to correct susceptibility distortions in spin-echo echo-planar images: application to diffusion tensor imaging. Neuroimage 2003;20:870–88 doi:10.1016/S1053-8119(03)00336-7 pmid:14568458

    CrossRefPubMedWeb of Science
18. 18.↵
    1. Smith SM,
    2. Jenkinson M,
    3. Woolrich MW, et al

    . Advances in functional and structural MR image analysis and implementation as FSL. Neuroimage 2004;23 Suppl 1:S208–19 doi:10.1016/j.neuroimage.2004.07.051 pmid:15501092

    CrossRefPubMed
19. 19.↵
    1. Basser PJ,
    2. Mattiello J,
    3. LeBihan D

    . Estimation of the effective self-diffusion tensor from the NMR spin echo. J Magn Reson B 1994;103:247–54 doi:10.1006/jmrb.1994.1037 pmid:8019776

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Fischl BFS

    . FreeSurfer. Neuroimage 2012;62:774–81 doi:10.1016/j.neuroimage.2012.01.021 pmid:22248573

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Rosen WG,
    2. Mohs RC,
    3. Davis KL

    . A new rating scale for Alzheimer's disease. Am J Psychiatry 1984;141:1356–64 doi:10.1176/ajp.141.11.1356 pmid:6496779

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Johnson KA,
    2. Schultz A,
    3. Betensky RA, et al

    . Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79:110–19 doi:10.1002/ana.24546 pmid:26505746

    CrossRefPubMed
23. 23.↵
    1. Cho H,
    2. Choi JY,
    3. Lee HS, et al

    . Progressive tau accumulation in Alzheimer disease: 2-year follow-up study. J Nucl Med 2019;60:1611–21 doi:10.2967/jnumed.118.221697 pmid:30926651

    Abstract/FREE Full Text
24. 24.↵
    1. Duara R,
    2. Loewenstein DA,
    3. Potter E, et al

    . Pre-MCI and MCI: neuropsychological, clinical, and imaging features and progression rates. Am J Geriatr Psychiatry 2011;19:951–60 doi:10.1097/JGP.0b013e3182107c69 pmid:21422909

    CrossRefPubMedWeb of Science
25. 25.↵
    1. Wen Q,
    2. Mustafi SM,
    3. Li J, et al

    . White matter alterations in early-stage Alzheimer’s disease: a tract-specific study. Alzheimers Dement (Amst) 2019;11:576–87 doi:10.1016/j.dadm.2019.06.003 pmid:31467968

    CrossRefPubMed
26. 26.↵
    1. Pierpaoli C,
    2. Basser PJ

    . Toward a quantitative assessment of diffusion anisotropy. Magn Reson Med 1996;36:893–906 doi:10.1002/mrm.1910360612 pmid:8946355

    CrossRefPubMedWeb of Science
27. 27.↵
    1. Colgan N,
    2. Siow B,
    3. O'Callaghan JM, et al

    . Application of neurite orientation dispersion and density imaging (NODDI) to a tau pathology model of Alzheimer's disease. Neuroimage 2016;125:739–44 doi:10.1016/j.neuroimage.2015.10.043 pmid:26505297

    CrossRefPubMed
28. 28.↵
    1. Montal V,
    2. Vilaplana E,
    3. Alcolea D, et al

    . Cortical microstructural changes along the Alzheimer’s disease continuum. Alzheimers Dement 2018;14:340–51 doi:10.1016/j.jalz.2017.09.013 pmid:29080407

    CrossRefPubMed
29. 29.↵
    1. Wolf D,
    2. Fischer FU,
    3. Scheurich A

    , Alzheimer’s Disease Neuroimaging Initiative, et al. Non-linear association between cerebral amyloid deposition and white matter microstructure in cognitively healthy older adults. J Alzheimers Dis 2015;47:117–27 doi:10.3233/JAD-150049 pmid:26402760

    Abstract/FREE Full Text
30. 30.↵
    1. Wells JA,
    2. O'Callaghan JM,
    3. Holmes HE, et al

    . In vivo imaging of tau pathology using multi-parametric quantitative MRI. Neuroimage 2015;111:369–78 doi:10.1016/j.neuroimage.2015.02.023 pmid:25700953

    CrossRefPubMed
31. 31.↵
    1. Weston PS,
    2. Simpson IJ,
    3. Ryan NS, et al

    . Diffusion imaging changes in grey matter in Alzheimer’s disease: a potential marker of early neurodegeneration. Alzheimers Res Ther 2015;7:47 doi:10.1186/s13195-015-0132-3

    CrossRefPubMed